Avacincaptad pegol
- Generic Name
- Avacincaptad pegol
- Brand Names
- Izervay
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1613641-69-2
- Unique Ingredient Identifier
- TT0V5JLG5B
- Background
Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule. It was developed to treat an advanced form of age-related macular degeneration (AMD) called geographic atrophy (GA). AMD is the leading cause of vision loss in developed countries for people over 50 years old, with a global estimate of 170 million individu...
- Indication
Avacincaptad pegol is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Associated Conditions
- Dry Macular Degeneration
- Associated Therapies
- -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT05536297
- Locations
- ๐บ๐ธ
Mid Atlantic Retina - Wills Eye Institute, Philadelphia, Pennsylvania, United States
๐บ๐ธRand Eye Institute, Deerfield Beach, Florida, United States
๐บ๐ธOchsner Clinic Foundation, New Orleans, Louisiana, United States
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
- Conditions
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- IVERIC bio, Inc.
- Target Recruit Count
- 448
- Registration Number
- NCT04435366
- Locations
- ๐บ๐ธ
Jules Stein Eye Institute/David Geffen School of Medicine, Los Angeles, California, United States
๐บ๐ธRetina and Vitreous of Texas, PLLC, Houston, Texas, United States
๐บ๐ธCincinnati Eye Institute, Cincinnati, Ohio, United States
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
- Conditions
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT03364153
- Locations
- ๐บ๐ธ
Retina Specialty Institute, Pensacola, Florida, United States
๐บ๐ธWilmer Eye Institute, Johns Hopkins, Baltimore, Maryland, United States
๐ซ๐ทCentre ophtalmologique des Quinzes Vingts, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.